Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

iBio, Kanematsu Chemicals Partner on Biologics Development, Production

By Drug Discovery Trends Editor | August 14, 2014

iBio Inc. and Kanematsu Chemicals Corp., part of Kanematsu Corp., have entered into a collaboration agreement under which Kanematsu Chemicals Corp. will market the novel iBioLaunch platform in Japan. 
 
The collaboration combines iBio’s plant-based expression system and expertise for rapid, reliable and economical development and production of biological vaccines and therapeutics, with the marketing reach and regional expertise of the life science group from Kanematsu Chemicals Corp. 
 
“The pharmaceutical business is one of the core businesses in which we are expecting further expansion, and the collaboration with iBio will lead Kanematsu Chemicals Corp. to its success,” said Kazuyuki Matsunaga, president of Kanematsu Chemicals Corp. “iBioLaunch has great potential to solve existing issues in the development and production of these products for the Japanese and export markets. We are very excited to start introducing this excellent technology to the Japanese pharmaceutical industry.” 
 
Japan commands 9% of global biologics sales (led only by the U.S. and the EU), a global market that is expected to grow to over $220 billion by 2019, according to TriMark Publications. 
 
Biologics can be categorized in three main groups: monoclonal antibodies, other therapeutic proteins, and vaccines. The iBioLaunch platform has been validated for production of each of these biologics categories. The iBioLaunch platform can enable companies producing either novel biologics or biosimilars to achieve competitive advantages over other expression systems due to its various attributes, including lower costs and scalability. 
 
“This agreement is an important part of our strategy to commercialize iBio’s proprietary technologies through collaboration with world-class partners,” said Robert Erwin, iBio’s president. “Together, Kanematsu Chemicals Corp. and iBio expect to bring the benefits of the unique enabling features of the iBioLaunch platform to the most innovative companies and important biologic products in the Japanese pharmaceutical industry.” 
 
Date: August 14, 2014
Source: iBio

Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE